Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioVersys AG ( (CH:BIOV) ) has issued an announcement.
BioVersys AG has announced its Annual General Meeting of Shareholders for 2025, scheduled for June 27 in Basel, Switzerland. Key agenda items include financial statements, board elections, and proposals to amend the company’s capital range to enhance strategic flexibility. The company also announced that Dr. Henni-Karoliina Ropponen will not seek re-election, with Dr. Ulrik Schulze proposed as her successor, expected to bolster the company’s expertise in capital markets and M&A.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF48.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of novel antibacterial products targeting multi-drug resistant bacteria. Utilizing its internal technology platforms, BioVersys aims to address unmet medical needs in the antimicrobial and microbiome fields, with advanced programs focused on nosocomial infections and tuberculosis.
Average Trading Volume: 1,530
See more data about BIOV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue